This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to potential clinical endpoint. Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the promise and challenges of MRD as a surrogate endpoint in AML, while Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, presents supporting evidence from large registry analyses.

Amin Turki, MD, PhD, Ruhr-University Hospital Bochum and University Hospital Essen, Essen, Germany, highlights the integration of MRD into risk stratification and treatment decision-making in AML. In ALL, Wendy Stock, MD, University of Chicago Medical Center, Chicago, IL, and Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss MRD detection methods, emerging technologies such as next-generation sequencing, and their impact on clinical practice.